神経バイオマーカーの市場規模、シェア、動向分析レポート：用途別、タイプ別、最終用途別、地域別、セグメント別予測、2025年～2030年

神経バイオマーカー市場の成長と動向

Grand View Research, Inc.の最新レポートによると、神経バイオマーカーの世界市場規模は、2025～2030年にかけてCAGR 12.9%で拡大し、2030年には187億5,000万米ドルに達する見込みです。

新薬開発を後押しする神経的バイオマーカーの研究開発に対する資金提供の増加が、市場成長を後押しすると予想されます。National Institute of Neurological Disorders and Strokeは、臨床検証、分析検証、バイオマーカー探索に関連する研究を行う研究者に、共同研究契約や研究開発助成金などの資金提供の機会を提供しています。

バイオマーカーは神経疾患治療の開発に重要な役割を果たしています。近年、神経疾患の治療法の研究開発への投資が大幅に増加しています。例えば、2020年12月には、非営利研究財団であるTarget ALSが、ALSの新規バイオマーカーの発見に焦点を当てたプロジェクトに1,500万米ドルの研究資金を提供することを発表しており、予測期間中の市場成長が加速すると予想されます。

高いS/N比を持つデジタル化ELISA検査であるQuanterix Simoa（単一分子アレイ）のような技術的に先進的な製品の登場。この技術は、神経疾患関連のバイオマーカーに関連する血液脳関門の問題を克服するのに役立ちます。このような技術的進歩は市場の成長を促進すると予想されます。例えば、アボット社は2021年1月、脳震盪を含む外傷性脳損傷のための初の迅速血液検査を発表しました。この検査は、外傷性脳損傷後に血液中に検出される特定のタンパク質を測定するもので、検査結果が陰性の場合、CTスキャンの必要性を除外するために使用できます。

このような診断製品に関する認知度の低さ、コストの高さ、特に新興諸国や低開発諸国における神経科医の不足や不在といった要因が、このようなバイオマーカーによる診断ソリューションの採用に影響を与える可能性があります。世界神経連合（World Federation of Neurology）がWHO加盟国63/84カ国を対象に行った調査によると、31/63カ国の神経科医の大多数は大都市に勤務していました。1人の神経科医が約6,240人から4,750,000人の人口にサービスを提供していました。

神経バイオマーカー市場レポートハイライト

• 2024年には、プロテオミクス型が最大の市場シェアを占め、予測期間中も優位性を維持すると予測されます。プロテオミクス型は、翻訳後修飾やタンパク質のシグネチャーを注意深く検出するため、疾患の発症や進行の正確な診断に不可欠だからです。
• パーキンソン病セグメントは、罹患率の上昇と研究開発活動の活発化により、最大の市場シェアを占めています。
• 最終用途別では、研究機関とその他セグメントが神経バイオマーカー市場を独占しました。神経疾患の治療開発のために共同研究を行っている研究機関は、薬剤耐性を評価するためにバイオマーカーを利用しています。
• 北米は、米国とカナダに強力なプレゼンスを持つ市場参入企業の存在と、新規バイオマーカー開発のための政府資金の増加により、市場を独占しています。
• アジア太平洋は、日本やオーストラリアのような先進国での技術的に先進的診断製品の高い採用率や、中国やインドのような新興経済諸国でのこれらの製品の採用増加により、予測期間中に大きな成長が見込まれています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 神経バイオマーカー市場の変数、動向、範囲

• 神経バイオマーカー市場の系統展望
  • 親市場の展望
• 浸透と成長の展望マッピング
• パイプライン分析
  • アルツハイマー病
  • パーキンソン病
  • 多発性硬化症
  • 自閉症スペクトラム障害
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 神経バイオマーカー：市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTLE分析

第4章 神経バイオマーカー市場：セグメント分析、タイプ別、2018～2030年

• 神経バイオマーカー市場：タイプ変動分析

第5章 神経バイオマーカー市場：セグメント分析、用途別、2018～2030年

• 神経バイオマーカー市場：用途変動分析

第6章 神経バイオマーカー市場：セグメント分析、最終用途別、2018～2030年

• 神経バイオマーカー市場：最終用途変動分析

第7章 神経バイオマーカー市場：地域別セグメント分析、2018～2030年

• 地域市場のスナップショット
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第8章 神経バイオマーカー市場：競合分析

• 企業分類
• 戦略マッピング
  • 新製品発売
  • パートナーシップ
  • 取得
  • コラボレーション
  • 資金調達
• 2022年の企業市場シェア分析
• 企業プロファイル
  • Abbott
  • Johnson & Johnson Services, Inc.
  • Bio-Rad Laboratories, Inc.
  • Alseres Pharmaceuticals, Inc.
  • Banyan Biomarkers, Inc.
  • Rules-Based Medicine
  • Thermo Fisher Scientific, Inc.
  • Diagenic Asa
  • Merck & Co., Inc.
  • Quanterix

List of Tables

• Table 1 List of Abbreviation
• Table 2 North America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 3 North America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 4 North America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 5 U.S. neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 6 U.S. neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 7 U.S. neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 8 Canada neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 9 Canada neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 10 Canada neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 11 Mexico neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 12 Mexico neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 13 Mexico neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 14 Europe neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 15 Europe neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 16 Europe neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 17 UK neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 18 UK neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 19 UK neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 20 Germany neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 21 Germany neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 22 Germany neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 23 France neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 24 France neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 25 France neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 26 Italy neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 27 Italy neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 28 Italy neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 29 Spain neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 30 Spain neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 31 Spain neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 32 Denmark neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 33 Denmark neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 34 Denmark neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 35 Sweden neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 36 Sweden neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 37 Sweden neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 38 Norway neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 39 Norway neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 40 Norway neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 44 Japan neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 45 Japan neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 46 Japan neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 47 China neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 48 China neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 49 China neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 50 India neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 51 India neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 52 India neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 53 South Korea neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 54 South Korea neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 55 South Korea neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 56 Australia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 57 Australia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 58 Australia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 59 Thailand neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 60 Thailand neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 61 Thailand neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 62 Latin America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 63 Latin America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 64 Latin America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 65 Brazil neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 66 Brazil neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 67 Brazil neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 68 Argentina neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 69 Argentina neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 70 Argentina neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 71 MEA neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 72 MEA neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 73 MEA neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 74 South Africa neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 75 South Africa neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 76 South Africa neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 77 Saudi Arabia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 78 Saudi Arabia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 79 Saudi Arabia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 80 UAE neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 81 UAE neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 82 UAE neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 83 Kuwait neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 84 Kuwait neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 85 Kuwait neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Neurological biomarkers market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Segment snapshot (Type and application)
• Fig. 11 Segment snapshot (End-use)
• Fig. 12 Competitive landscape snapshot
• Fig. 13 Biomarkers market value, 2022 (USD Million)
• Fig. 14 Neurological biomarkers market dynamics
• Fig. 15 Prevalence of Alzheimer's disease by age group, 2024
• Fig. 16 Neurological biomarkers market: PORTER's analysis
• Fig. 17 Neurological biomarkers market: PESTLE analysis
• Fig. 18 Neurological biomarkers market: Type outlook and key takeaways
• Fig. 19 Neurological biomarkers market: Type movement analysis
• Fig. 20 Genomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Proteomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Metabolomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Imaging market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Other neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Neurological biomarkers market: Application outlook and key takeaways
• Fig. 26 Neurological biomarkers market: Application movement analysis
• Fig. 27 Alzheimer's disease market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Parkinson's disease market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Multiple sclerosis market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Autism spectrum disorder market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Neurological biomarkers market: End-use outlook and key takeaways
• Fig. 33 Neurological biomarkers market: End-use movement analysis
• Fig. 34 Research Organizations market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Pharma & Biotech Companies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Clinical Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Neurological biomarkers market revenue, by region, 2022 & 2030 (USD Million)
• Fig. 38 Regional marketplace: Key takeaways
• Fig. 39 Regional marketplace: Key takeaways
• Fig. 40 North America market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 41 Key country dynamics
• Fig. 42 U.S. neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 Target disease prevalence
• Fig. 44 Key country dynamics
• Fig. 45 Canada neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 46 Target disease prevalence
• Fig. 47 Europe neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 48 Key country dynamics
• Fig. 49 UK neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 50 Key country dynamics
• Fig. 51 Germany neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 52 Target disease prevalence
• Fig. 53 Key country dynamics
• Fig. 54 France neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 55 Key country dynamics
• Fig. 56 Italy neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 57 Key country dynamics
• Fig. 58 Spain neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 59 Key country dynamics
• Fig. 60 Denmark neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 61 Key country dynamics
• Fig. 62 Sweden neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 63 Key country dynamics
• Fig. 64 Norway neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 65 Target disease prevalence
• Fig. 66 Rest of Europe market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 67 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 68 Key country dynamics
• Fig. 69 Japan neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 70 Target disease prevalence
• Fig. 71 Key country dynamics
• Fig. 72 China neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 73 Key country dynamics
• Fig. 74 India neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 75 Target disease prevalence
• Fig. 76 Key country dynamics
• Fig. 77 Australia neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 78 Key country dynamics
• Fig. 79 Thailand neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 80 Key country dynamics
• Fig. 81 South Korea neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 82 Rest of Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 83 Latin America neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Key country dynamics
• Fig. 85 Brazil neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Key country dynamics
• Fig. 87 Mexico neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Key country dynamics
• Fig. 89 Argentina neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Rest of Latin America neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 91 MEA neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Key country dynamics
• Fig. 93 South Africa neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 94 Target disease prevalence
• Fig. 95 Key country dynamics
• Fig. 96 Saudi Arabia neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 97 Target disease prevalence
• Fig. 98 Key country dynamics
• Fig. 99 UAE neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 100 Target disease prevalence
• Fig. 101 Key country dynamics
• Fig. 102 Kuwait neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 103 Target disease prevalence
• Fig. 104 Key payors in Kuwait
• Fig. 105 Rest of MEA neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 106 Key company categorization
• Fig. 107 Company market positioning
• Fig. 108 Company market share analysis, 2022
• Fig. 109 Strategic framework

Neurological Biomarkers Market Growth & Trends:

The global neurological biomarkers market size is expected to reach USD 18.75 billion by 2030, expanding at a CAGR of 12.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increased funding for R&D of neurological biomarkers to boost development of new drugs is expected to impel market growth. National Institute of Neurological Disorders and Stroke provides funding opportunities such as cooperative agreements & development grants for researchers conducting studies related to clinical validation, analytical validation, & biomarker discovery.

Biomarkers play a significant role in the development of drugs for the treatment of neurological diseases. In recent years, there has been a significant rise in investments in the R&D of treatments for neurological diseases. For instance, in December 2020, Target ALS-a nonprofit research foundation-announced research funding of USD 15 million for a project focused on the discovery of novel biomarkers for ALS, which is anticipated to accelerate market growth in the forecast period.

Availability of technologically advanced products such as Quanterix Simoa (single-molecule array), which is a digitized ELISA test with a high signal-to-noise ratio. This technology helps overcome blood-brain barrier issues associated with neurological disease-related biomarkers. Such technological advancements are expected to drive market growth. For instance, in January 2021, Abbott introduced the first rapid blood test for traumatic brain injury, including concussion. This test measures a particular protein that is found in the blood after a traumatic brain injury and can be used to rule out the need for CT scanning in case of negative test results.

Factors such as lack of awareness about such diagnostic products & their high cost and limited availability or absence of neurologists, especially in developing & underdeveloped countries, could affect the adoption of such biomarker-based diagnostic solutions. According to a World Federation of Neurology survey of 63/84 WHO member countries, the majority of neurologists in 31/63 countries worked in major cities. One neurologist was serving a population of about 6,240 to 4,750,000.

Neurological Biomarkers Market Report Highlights:

• In 2024, proteomic type accounted for the largest market share and is anticipated to maintain their dominance over the forecast period as these are essential for accurate diagnosis of disease onset and progression due to the careful detection of posttranslational modifications and protein signatures
• Parkinson's disease segment held the largest market share owing to rising incidence and increasing R&D activities.
• Based on end use, the research organizations and others segment dominated the neurological biomarkers market. Research organizations collaborating for the development of therapeutics for treating neurological disorders utilize biomarkers for assessing the drug tolerance.
• North America dominated the market owing to presence of market players with strong presence in the U.S. & Canada, and increasing government funding for the development of novel biomarkers
• Asia-Pacific is anticipated to witness significant growth over the forecast period owing to high adoption of technologically advanced diagnostic products in developed countries such as Japan & Australia and increasing adoption of these products in developing economies such as China and India.

Table of Contents

Chapter 1 Methodology And Scope

• 1.1 Market Segmentation And Scope
  • 1.1.1 Segment Definition
    • 1.1.1.1 Application Segment
    • 1.1.1.2 Type Segment
    • 1.1.1.3 End Use Segment
• 1.2 Regional Scope
• 1.3 Estimates And Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 Gvr's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Outlook
• 2.2 Application And Type Snapshot
• 2.3 End Use Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 Neurological Biomarkers Market Variables, Trends, And Scope

• 3.1 Neurological Biomarkers Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 Penetration And Growth Prospect Mapping
• 3.3 Pipeline Analysis
  • 3.3.1 Alzheimer's Disease
  • 3.3.2 Parkinson's Disease
  • 3.3.3 Multiple Sclerosis
  • 3.3.4 Autism Spectrum Disorder
• 3.4 Market Dynamics
  • 3.4.1 Market Driver Analysis
    • 3.4.1.1 Increasing Prevalence Of Neurological Diseases
    • 3.4.1.2 Technological Advancements
    • 3.4.1.3 Increased Funding For R&D In Biomarkers
  • 3.4.2 Market Restraint Analysis
    • 3.4.2.1 Lack Of Consumer Awareness
    • 3.4.2.2 Reimbursement Policies
• 3.5 Neurological Biomarkers: Market Analysis Tools
  • 3.5.1 Industry Analysis - Porter's
  • 3.5.2 Pestle Analysis

Chapter 4 Neurological Biomarkers Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)

• 4.1 Neurological Biomarkers Market: Type Movement Analysis
  • 4.1.1 Genomic
    • 4.1.1.1 Genomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 4.1.2 Proteomic
    • 4.1.2.1 Proteomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 4.1.3 Metabolomic
    • 4.1.3.1 Metabolomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 4.1.5 Imaging
    • 4.1.5.1 Imaging Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 4.1.6 Others
    • 4.1.6.1 Others Neurological Biomarkers Market, 2018 - 2030 (USD Million)

Chapter 5 Neurological Biomarkers Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

• 5.1 Neurological Biomarkers Market: Application Movement Analysis
  • 5.1.1 Alzheimer's Disease
    • 5.1.1.1 Alzheimer's Disease Market, 2018 - 2030 (USD Million)
  • 5.1.2 Parkinson's Disease
    • 5.1.2.1 Parkinson's Disease Market, 2018 - 2030 (USD Million)
  • 5.1.3 Multiple Sclerosis
    • 5.1.3.1 Multiple Sclerosis Market, 2018 - 2030 (USD Million)
  • 5.1.4 Autism Spectrum Disorder
    • 5.1.4.1 Autism Spectrum Disorder Market, 2018 - 2030 (USD Million)
  • 5.1.5 Others
    • 5.1.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Neurological Biomarkers Market: Segment Analysis, By End Use, 2018 - 2030 (USD Million)

• 6.1 Neurological Biomarkers Market: End Use Movement Analysis
  • 6.1.1 Research Organizations
    • 6.1.1.1 Research Organizations Market, 2018 - 2030 (USD Million)
  • 6.1.2 Pharma & Biotech Companies
    • 6.1.2.1 Pharma & Biotech Companies Market, 2018 - 2030 (USD Million)
  • 6.1.3 Clinical Diagnostics
    • 6.1.3.1 Clinical Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 7 Neurological Biomarkers Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

• 7.1 Regional Market Snapshot
• 7.2 North America
  • 7.2.1 North America Neurological Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.2.2 U.S.
    • 7.2.2.1 U.S. Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.2.2.2 Key Country Dynamics
    • 7.2.2.3 Regulatory Framework
    • 7.2.2.4 Reimbursement Scenario
  • 7.2.3 Canada
    • 7.2.3.1 Canada Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.2.3.2 Key Country Dynamics
    • 7.2.3.3 Regulatory Framework
    • 7.2.3.4 Reimbursement Scenario
  • 7.2.4 Mexico
    • 7.2.4.1 Mexico Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.2.4.2 Key Country Dynamics
    • 7.2.4.3 Regulatory Framework
    • 7.2.4.4 Reimbursement Scenario
• 7.3 Europe
  • 7.3.1 Europe Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.3.2 Uk
    • 7.3.2.1 Uk Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.2.2 Key Country Dynamics
    • 7.3.2.3 Regulatory Framework
    • 7.3.2.4 Reimbursement Scenario
  • 7.3.3 Germany
    • 7.3.3.1 Germany Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.3.2 Key Country Dynamics
    • 7.3.3.3 Regulatory Framework
    • 7.3.3.4 Reimbursement Scenario
  • 7.3.4 Spain
    • 7.3.4.1 Spain Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.4.2 Key Country Dynamics
    • 7.3.4.3 Regulatory Framework
    • 7.3.4.4 Reimbursement Scenario
  • 7.3.5 France
    • 7.3.5.1 France Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.5.2 Key Country Dynamics
    • 7.3.5.3 Regulatory Framework
    • 7.3.5.4 Reimbursement Scenario
  • 7.3.6 Italy
    • 7.3.6.1 Italy Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.6.2 Key Country Dynamics
    • 7.3.6.3 Regulatory Framework
    • 7.3.6.4 Reimbursement Scenario
  • 7.3.7 Denmark
    • 7.3.7.1 Denmark Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.7.2 Key Country Dynamics
    • 7.3.7.3 Regulatory Framework
    • 7.3.7.4 Reimbursement Scenario
  • 7.3.8 Sweden
    • 7.3.8.1 Sweden Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.8.2 Key Country Dynamics
    • 7.3.8.3 Regulatory Framework
    • 7.3.8.4 Reimbursement Scenario
  • 7.3.9 Norway
    • 7.3.9.1 Norway Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.9.2 Key Country Dynamics
    • 7.3.9.3 Regulatory Framework
    • 7.3.9.4 Reimbursement Scenario
• 7.4 Asia Pacific
  • 7.4.1 Asia-Pacific Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.4.2 Japan
    • 7.4.2.1 Japan Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.2.2 Key Country Dynamics
    • 7.4.2.3 Regulatory Framework
    • 7.4.2.4 Reimbursement Scenario
  • 7.4.3 China
    • 7.4.3.1 China Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.3.2 Key Country Dynamics
    • 7.4.3.3 Regulatory Framework
    • 7.4.3.4 Reimbursement Scenario
  • 7.4.4 India
    • 7.4.4.1 India Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.4.2 Key Country Dynamics
    • 7.4.4.3 Regulatory Framework
    • 7.4.4.4 Reimbursement Scenario
  • 7.4.5 South Korea
    • 7.4.5.1 South Korea Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.5.2 Key Country Dynamics
    • 7.4.5.3 Regulatory Framework
    • 7.4.5.4 Reimbursement Scenario
  • 7.4.6 Thailand
    • 7.4.6.1 Thailand Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.6.2 Key Country Dynamics
    • 7.4.6.3 Regulatory Framework
    • 7.4.6.4 Reimbursement Scenario
  • 7.4.7 Australia
    • 7.4.7.1 Australia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.7.2 Key Country Dynamics
    • 7.4.7.3 Regulatory Framework
    • 7.4.7.4 Reimbursement Scenario
• 7.5 Latin America
  • 7.5.1 Latin America Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.5.2 Brazil
    • 7.5.2.1 Brazil Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.5.2.2 Key Country Dynamics
    • 7.5.2.3 Regulatory Framework
    • 7.5.2.4 Reimbursement Scenario
  • 7.5.3 Argentina
    • 7.5.3.1 Argentina Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.5.3.2 Key Country Dynamics
    • 7.5.3.3 Regulatory Framework
    • 7.5.2.4 Reimbursement Scenario
• 7.6 MEA
  • 7.6.1 MEA Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.6.2 South Africa
    • 7.6.2.1 South Africa Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.2.2 Key Country Dynamics
    • 7.6.2.3 Regulatory Framework
    • 7.6.2.4 Reimbursement Scenario
  • 7.6.3 Saudi Arabia
    • 7.6.3.1 Saudi Arabia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.3.2 Key Country Dynamics
    • 7.6.3.3 Regulatory Framework
    • 7.6.3.4 Reimbursement Scenario
  • 7.6.4 UAE
    • 7.6.4.1 UAE Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.4.2 Key Country Dynamics
    • 7.6.4.3 Regulatory Framework
    • 7.6.2.4 Reimbursement Scenario
  • 7.6.5 Kuwait
    • 7.6.5.1 Kuwait Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.5.2 Key Country Dynamics
    • 7.6.5.3 Regulatory Framework
    • 7.6.5.4 Reimbursement Scenario

Chapter 8 Neurological Biomarkers Market: Competitive Analysis

• 8.1 Company Categorization
• 8.2 Strategy Mapping
  • 8.2.1 New Product Launch
  • 8.2.2 Partnerships
  • 8.2.3 Acquisition
  • 8.2.4 Collaboration
  • 8.2.5 Funding
• 8.3 Company Market Share Analysis, 2022
• 8.4 Company Profiles
  • 8.4.1 Abbott
    • 8.4.1.1 Company Overview
    • 8.4.1.2 Financial Performance
    • 8.4.1.3 Product Benchmarking
    • 8.4.1.4 Strategic Initiatives
  • 8.4.2 Johnson & Johnson Services, Inc.
    • 8.4.2.1 Company Overview
    • 8.4.2.2 Financial Performance
    • 8.4.2.3 Product Benchmarking
    • 8.4.2.4 Strategic Initiatives
  • 8.4.3 Bio-Rad Laboratories, Inc.
    • 8.4.3.1 Company Overview
    • 8.4.3.2 Financial Performance
    • 8.4.3.3 Product Benchmarking
    • 8.4.3.4 Strategic Initiatives
  • 8.4.4 Alseres Pharmaceuticals, Inc.
    • 8.4.4.1 Company Overview
    • 8.4.4.2 Product Benchmarking
  • 8.4.5 Banyan Biomarkers, Inc.
    • 8.4.5.1 Company Overview
    • 8.4.5.2 Product Benchmarking
    • 8.4.5.3 Strategic Initiatives
  • 8.4.6 Rules-Based Medicine
    • 8.4.6.1 Company Overview
    • 8.4.6.2 Financial Performance
    • 8.4.6.3 Product Benchmarking
    • 8.4.6.4 Strategic Initiatives
  • 8.4.7 Thermo Fisher Scientific, Inc.
    • 8.4.7.1 Company Overview
    • 8.4.7.2 Financial Performance
    • 8.4.7.3 Product Benchmarking
    • 8.4.7.4 Strategic Initiatives
  • 8.4.8 Diagenic Asa
    • 8.4.8.1 Company Overview
    • 8.4.8.2 Product Benchmarking
  • 8.4.9 Merck & Co., Inc.
    • 8.4.9.1 Company Overview
    • 8.4.9.2 Financial Performance
    • 8.4.9.3 Product Benchmarking
    • 8.4.9.4 Strategic Initiatives
  • 8.4.10 Quanterix
    • 8.4.10.1 Company Overview
    • 8.4.10.2 Product Benchmarking
    • 8.4.10.3 Strategic Initiatives